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Community-associated methicillin-resistant Staphylo-
coccus aureus (MRSA) was first reported in Western
Australia in the early 1990s from indigenous peoples living
in remote areas. Although a statewide policy of screening
all hospital patients and staff who have lived outside the
state for MRSA has prevented the establishment of mul-
tidrug-resistant epidemic MRSA, the policy has not pre-
vented SCCmec type IV and type V MRSA clones from
becoming established. Of the 4,099 MRSA isolates ana-
lyzed (referred to the Gram-positive Bacteria Typing and
Research Unit) from July 2003 to December 2004, 77.5%
were community-associated MRSA (CA-MRSA). Using
multilocus sequence/staphylococcal chromosome cassette
mec typing, 22 CA-MRSA clones were characterized. Of
these isolates, 55.5% were resistant to >1 non–β-lactam
antimicrobial drug. Five Panton-Valentine leukocidin
(PVL)–positive CA-MRSA clones were identified. The
emergence of multidrug-resistant CA-MRSAclones and the
detection of PVL toxin genes in clones previously reported
as PVL negative is a major public health concern.
S
taphylococcus aureus successfully colonizes humans,
contaminates the hospital environment, and has the
genetic versatility to acquire resistance to multiple antimi-
crobial agents. Methicillin-resistant S. aureus (MRSA)
was first detected soon after the introduction of methicillin
in 1960, and isolation rates increased until the early 1970s
(1). These earlier “classic” MRSA strains were genetically
similar to each other and may have evolved from a single
clone (2). In 1976, the first outbreak of gentamicin-resist-
ant MRSA in Australia (3) was reported, and by 1981
extensive outbreaks occurred in several countries. In 1985,
it became evident that these “modern” strains of MRSA
carried epidemic potential not possessed by MRSA isolat-
ed in the 1960s and early 1970s and that they were genet-
ically different from the earlier classic MRSA (4). Since
1990, international and intercontinental spread of MRSA
(known as epidemic MRSA or EMRSA) has increased. In
2002, Enright et al., using multilocus sequence typing
(MLST) combined with staphylococcal chromosome cas-
sette mec (SCCmec) typing, established that relatively few
major EMRSA clones existed (5). These clones emerged
either as descendants of preexisting EMRSA clones or by
horizontal transfer of the mec determinants into methi-
cillin-susceptible S. aureus.
EMRSA became endemic in hospitals in eastern
Australian states (New South Wales, Victoria, and
Queensland) in the late 1980s and 1990s, with some spread
to hospitals in South Australia, the Northern Territory, and
Tasmania (6). However, a statewide MRSA policy, intro-
duced in 1982, prevented these strains from becoming
established in Western Australia (WA) hospitals. This pol-
icy required MRSA screening of anyone who had been
hospitalized or had been a healthcare worker in a hospital
outside of WA in the previous 12 months. MRSA-positive
patients were isolated in the hospital, and staff with
MRSA-positive test results received decolonization treat-
ment. Imported MRSA still occasionally caused single-
strain outbreaks in hospitals; however, infection control
interventions contained them.
In the early 1990s, nonmultidrug-resistant MRSA
(nmMRSA) were observed in WA, initially from indige-
nous people in remote communities (7) but subsequently in
Perth, the state capital. These strains became known as
“WA-MRSA.” Although WA-MRSA did not readily
spread in WAhospitals, 1 strain was responsible for an out-
break of hospital-acquired infection (8). Strains of
nmMRSA have recently been reported in the eastern
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AustraliaAustralian states, and studies in Queensland and New
South Wales showed a strong association between commu-
nity-acquired infection with nmMRSAand Polynesian eth-
nicity. Isolates causing these infections were
indistinguishable by phage typing and pulsed-field gel
electrophoresis from those previously reported in New
Zealand (9,10). Subsequently, a second strain (WA-
MRSA-7 or Qld MRSA) has been associated with commu-
nity-acquired infections in Caucasians in Queensland (11).
The emergence of nmMRSA has also been reported in
other parts of the world, including North America (12) and
Europe (13). Although nmMRSA strains appear to have
originated in the community, they may include nmEMRSA
strains that have been associated with healthcare facilities
(e.g., EMRSA-15, EMRSA-16, and the New York/Japan
EMRSA) or nonmultidrug-resistant sporadic hospital
MRSA strains that have been taken into the community.
In 1997, the Department of Health WA, in collaboration
with the Department of Microbiology and Infectious
Diseases at Royal Perth Hospital, PathWest Laboratory
Medicine WA, and the School of Biomedical Sciences at
Curtin University of Technology established the Gram-
positive Bacteria Typing and Research Unit to assist in
controlling MRSA in WA. Since then, all MRSA isolated
in WAhave been referred to the unit for epidemiologic typ-
ing. This study describes the different epidemic and CA-
MRSA clones isolated in WA and establishes their genetic
relatedness.
Materials and Methods
MRSA Isolates
All MRSA isolated in WA between July 1, 2003, and
December 31, 2004, were included in this study. Isolates
were recovered from clinical and infection control screen-
ing specimens. For the purpose of this study, duplicate
isolates from the same patient (as determined by their
antimicrobial drug susceptibility phenotype) were
excluded.
Antimicrobial Susceptibility Testing
A test for oxacillin susceptibility was performed on
Mueller-Hinton agar by the disk diffusion method accord-
ing to Clinical Laboratory Standards Institute (CLSI) rec-
ommendations by using a 1-µg oxacillin disk (14).
Oxacillin susceptibility results discrepant with those of the
referring laboratory were confirmed by the detection of the
mecA gene by polymerase chain reaction (PCR) (15).
An antibiogram was performed on Mueller-Hinton agar
by the disk diffusion method according to CLSI recom-
mendations, against a panel of 8 antimicrobial drugs (14):
erythromycin (15 µg), tetracycline (30 µg), trimethoprim
(5 µg), ciprofloxacin (5 µg), gentamicin (10 µg), rifampin
(5 µg), fusidic acid (10 µg), and mupirocin (5 µg). The
French CA-SFM susceptibility testing interpretive criteri-
on was used for fusidic acid (16), and the suggested inter-
pretive criterion by Finlay et al. was used for mupirocin
(17). CLSI interpretive criteria were used for the remain-
ing antimicrobial drugs (18). MRSA that were resistant to
>3 of the 8 antimicrobial drugs listed were defined as
mMRSA and those resistant to <3 drugs were defined as
nmMRSA (8). Urease production was performed by
Christensen’s urea slopes incubated for 24 h at 37°C.
Typing Methods
Resistogram typing was performed by disk diffusion
against a panel of 6 chemicals and dyes: cadmium acetate
(10 mmol/L), sodium arsenate (0.2 µmol/L), ethidium bro-
mide (15 mmol/L), propamidine isethionate (2% [wt/vol]),
mercuric chloride (0.4 µmol/L), and phenylmercuric
acetate (5 mmol/L) as previously described (19,20).
Coagulase gene restriction fragment length polymor-
phism (RFLP) typing was performed as previously
described (21). Contour-clamped homogeneous electric
field electrophoresis (CHEF) was performed as previously
described with the CHEF DR III System (Bio-Rad
Laboratories Pty Ltd, Regents Park, New South Wales) (8).
Chromosomal patterns were examined visually, scanned
with a Fluor-S Multimager (Bio-Rad Laboratories), and
digitally analyzed with Multi-Analyst/PC (Bio-Rad
Laboratories). CHEF patterns were grouped according to
the criteria of Tenover et al. (22) and using a dendrogram
similarity of >80% to assign strain relatedness. S. aureus
NCTC8325 was used as the size marker.
Multilocus sequence typing (MLST) was performed as
specified by Enright et al. (23) on randomly selected iso-
lates within each pulsotype. To assign a sequence type
(ST) the sequences obtained were compared with the
sequences described on the MLST website (http:www.
mlst.net/). Using the MLST database, clones were subse-
quently grouped into clonal complexes (CC). 
SCCmec typing was performed by PCR by using previ-
ously published primers that identified the class of mec
complex and type of cassette chromosome recombinase
(ccr) encoded on the element (24,25). The presence of the
Panton-Valentine leukocidin (PVL) determinants were
detected by PCR by using previously published primers
(26) and confirmed by sequencing the products.
Results
A total of 4,099 MRSA isolates were studied. All iso-
lates were initially grouped according to their antibiogram
and urease production. Isolates within a group were then
further characterized by using coagulase PCR-RFLP and
CHEF analysis. MLST/SCCmec typing and PVL detection
were performed on randomly selected isolates within each
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(22.5%) EMRSA clones and 22 (77.5%) CA-MRSA
clones.
EMRSA Clones
Table 1 shows the 7 EMRSA clones identified: ST22-
MRSA-IV (EMRSA-15), ST239-MRSA-III (Aus-2 and
Aus-3 EMRSA), ST8-MRSA-IVpediatric (Irish-2 EMRSA),
ST36-MRSA-II (EMRSA-16), ST5-MRSA-II (New
York/Japan EMRSA), ST8-MRSA-IIvariant (Irish-1
EMRSA), and the classic MRSA clone ST250-MRSA-I.
Only 3 EMRSA clones were typically multidrug-resistant:
ST239-MRSA-III (resistant to tetracycline, erythromycin,
trimethoprim, ciprofloxacin, and gentamicin), ST8-
MRSA-IVpediatric (resistant to erythromycin, trimethoprim,
and ciprofloxacin), and ST8-MRSA-IIvariant (resistant to
tetracycline, erythromycin, trimethoprim, ciprofloxacin,
gentamicin and mupirocin). 
Overall, 94.6% of EMRSA were identified either as
ST22-MRSA-IV (78.1%), a urease-negative nmEMRSA
clone (resistant to erythromycin and ciprofloxacin) or
ST239-MRSA-III (16.5%). By using CHEF electrophore-
sis and resistogram typing, ST239-MRSA-III could be fur-
ther classified into 2 subclones: Aus-2 EMRSA
(susceptible to mercuric chloride and phenylmercuric
acetate) and Aus-3 EMRSA (resistant to mercuric chloride
and phenylmercuric acetate).
CA-MRSA
Of the 22 identified clones of CA-MRSA, 21 were WA-
MRSA and 1 was Western Samoan phage pattern (WSPP)
MRSA (Table 2). By using CHEF electrophoresis, ST8-
MRSA-IV and ST5-MRSA-V could be further classified
into WA-MRSA-5 and WA-MRSA-12, and WA-MRSA-11
and WA-MRSA-14 pulsotypes, respectively.
Overall, 93.7% of CA-MRSA were classified into 3
clones: ST1-MRSA-IV (55.3%), ST129-MRSA-IV
(29.8%), and ST5-MRSA-IV (8.6%). Of the CA-MRSA,
97.3% were SCCmec type IV and 2.6% SCCmec type V.
Four isolates carrying novel SCCmec type(s) were found
in 2 STs (ST5 and ST8). Using the MLST database, the 22
clones were grouped into 10 CCs and 2 singletons.
Five clones (2.3% of CA-MRSA) were PVL positive
including ST30-MRSA-IV and ST93-MRSA-IV. These 2
clones were originally reported outside WA, ST30-MRSA-
IV in New Zealand and ST93-MRSA-IV in Queensland.
The remaining 3 clones, ST8-MRSA-IV(MRSA-12 pulso-
type), ST59-MRSA-IV, and ST583-MRSA-IV accounted
for only 0.3% of CA-MRSA isolated in WA.
CA-MRSA Antibiograms
The online Appendix Table (available from http://www.
cdc.gov/ncidod/eid/vol12no02/05-0454_app.htm) shows 6
of the 22 CA-MRSA clones (17 isolates) were predictably
resistant to β-lactam antimicrobial drugs only. In the
remaining 16 clones, 55.9% of isolates were resistant to at
least 1 non–β-lactam antimicrobial drug, including 47.7%
to erythromycin, 10.8% to fusidic acid, 2.9% to
ciprofloxacin, 2.5% to trimethoprim, 1.8% to tetracycline,
1.6% to gentamicin, 1.3% to mupirocin, and 0.2% to
rifampin. In 6 of these clones, 1.5% of isolates were clas-
sified as multidrug-resistant. None of the 73 isolates found
in PVL-positive clones were multidrug-resistant: 7% of
ST30-MRSA-IV were resistant to rifampin, 15% of ST93-
MRSA-IV were resistant to erythromycin, 50% of ST583-
MRSA-IV were resistant to fusidic acid and tetracycline,
and 50% were resistant to fusidic acid and erythromycin;
all the ST59-MRSA-V were resistant to tetracycline and
erythromycin, and 75% and 25% of ST8-MRSA-IV
(MRSA-12 pulsotype) were resistant to erythromycin and
tetracycline, respectively. The 11 strains classified as ST5-
MRSA-V (WA-MRSA-11 pulsotype) were all resistant to
gentamicin. This strain was involved in a single strain out-
break in a burn unit.
Discussion
In WA, colonization or infection with MRSA has been
a notifiable condition since 1982, which has enabled the
rapid and widespread emergence of CA-MRSAto be mon-
itored. In rural areas, the overall MRSA notification rate
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542/100,000 persons in 2002. Similarly, in the same peri-
od rates increased in the Perth metropolitan area from
7/100,000 to 520/100,000. Although part of this increase in
the metropolitan area from 1998 was due to an increase in
EMRSA notifications, most can be attributed to CA-
MRSA (unpub. data).
In this study, 22.5% (n = 921) of MRSA isolates were
classified as EMRSA. Six international epidemic clones
and the classic MRSA clone, ST250-MRSA-I, were iden-
tified (Table 1). More than 78% of EMRSA isolates were
identified as ST22-MRSA-IV (EMRSA-15), an
nmEMRSA with the community type IV SCCmec.
Originally described in the United Kingdom in the early
1990s and now the predominant epidemic strain in that
country (27), ST22-MRSA-IV was first isolated in WA in
1997 in preemployment screening of healthcare workers
coming from the United Kingdom and Ireland (28).
Notifications have increased from 55 in 1998 to 383 in
2002 (unpub. data). Although recent national surveillance
studies have also reported the emergence of ST22-MRSA-
IV in other Australian states (29), the predominant
EMRSAin most Australian capital cities is ST239-MRSA-
III (30). The 6 epidemic clones reported in this study have
6 STs which can be grouped into 4 of the 5 major epidem-
ic CCs described by Enright et al. (5), CC5, CC8, CC22,
and CC30. CC8 also includes the ancestral MRSA geno-
type ST250-MRSA-I, which evolved from the methicillin-
susceptible strain ST250-MSSA, which is thought to have
arisen from ST8-MSSA by a chromosomal mutation (5).
Other STs isolated in this study, which form part of CC8,
were ST8-MRSA-IVpediatric, ST8-MRSA-IIvariant, and
ST239-MRSA-III. ST5-MRSA-II, ST22-MRSA-IV, and
ST36-MRSA-II belong to CC5, CC22, and CC30, respec-
tively.
CA-MRSA made up 77.5% of the isolates. These
MRSA have several characteristics that differentiate them
from most nosocomial MRSA. They harbor a smaller,
SCCmec (SCCmec IV and V), are susceptible to most
antimicrobial drugs other than the β-lactam agents, and are
more likely to encode the virulence factor PVL (31).
In this study, 21 clones of WA-MRSA were identified
by MLST/SCCmec typing with further delineation into 23
chromosomal DNA pulsotypes and numerous pulsosub-
types by CHEF. Also identified was the Western Pacific
CA-MRSA (ST30-MRSA-IV) first isolated in Auckland,
New Zealand (32). CA-MRSA from different parts of the
world has been reported with varied genetic backgrounds
(24). The results presented here demonstrate that this
is also the case for CA-MRSA isolated within a single
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CCs (CC1, CC5, CC8, CC9, CC30, CC45, CC59, CC78,
CC80, and CC121) and 2 singletons (ST75-MRSA-IV and
ST93-MRSA-IV). The 10 CCs identified include 4 of the
5 major epidemic CCs (CC5, CC8, CC30, and CC45). Five
CCs had >1 clone (2 clones in CC1 and CC45, 3 clones in
CC8 and CC59, and 5 clones in CC5).
The 2 predominant CA-MRSA clones isolated were
ST1-MRSA-IV and ST129-MRSA-IV (55.3% and 29.8%
of CA-MRSA, respectively). ST1-MRSA-IV belongs to
CC1, which has the same allelic profile as the S. aureus
that is the proposed ancestor of MW2 CA-MRSA that was
responsible for the deaths of 4 children in the United States
(33). CC1 CA-MRSA has also been reported in France
(13) and other areas of Australia (24), which indicates that
this clone is particularly successful. ST129-MRSA-IV
belongs to CC78, a smaller CC that includes strains isolat-
ed elsewhere in Australia, Portugal, and Japan
(http://www.mlst.net).
Despite the diversity of CCs, the CA-MRSA strains
were remarkably uniform in their SCCmec  allotypes.
SCCmec IV was identified in 14 STs and SCCmec V was
identified in 5. This suggests that in WA these 2 allotypes
are well adapted to the community environment. Two STs
were found to have novel SCCmec types.
Unlike SCCmec types II and III, which carry a number
of inserted plasmids and transposons downstream of the
mecA complex, community-associated SCCmec types IV
and V are smaller and lack other resistance genes.
However, resistance may be encoded elsewhere on the
chromosome or the isolate may carry resistance plasmids.
Although CA-MRSA isolated in WA is typically nonmul-
tidrug-resistant, all strains harbor a large plasmid that
varies in size (34). This plasmid encodes determinants for
β-lactamase production and cadmium resistance. In addi-
tion, some isolates have been reported to carry a 41.4-kb
plasmid that also encodes β-lactamase and resistance to
mupirocin, tetracycline, trimethoprim, and cadmium and a
smaller plasmid (2 kb) that encodes inducible erythromy-
cin resistance (34). Chromosomal fusidic acid and tetracy-
cline resistance determinants have also been reported (34);
however, the location of these determinants on the chro-
mosome is unknown. In this study, 44% of CA-MRSA
were resistant to β-lactam antimicrobial drugs only. Of the
remaining 56%, 54.5% were also resistant to 1–2 non–β-
lactam agents, and 1.5% to >3 non–β-lactam agents,
including 3 isolates resistant to 5 additional antimicrobial
drugs (online Appendix Table).
CA-MRSA have been shown to express several viru-
lence genes, including the determinants for PVL(35). PVL
is a necrotizing toxin that causes leukocyte destruction and
tissue necrosis and is associated with abscesses and severe
pneumonia. PVLis present in most of the CA-MRSAstud-
ied in Europe and the United States (13). In WA, CA-
MRSA infrequently carries the genes encoding PVL (34);
however, 2 CA-MRSA clones, ST30-MRSA-IV, and
ST93-MRSA-IV, more commonly isolated in eastern
Australia are PVL positive. ST30-MRSA-IV was first
noted in Australia in 1997 in the Polynesian population liv-
ing in the eastern Australian states and the Australian
Capital Territory (9). ST93-MRSA-IV was first identified
as a cause of community-acquired infection in the
Caucasian population in Ipswich, Queensland, in 2000
(11). Both clones are now frequently isolated in several
areas of Australia (29). In WA, ST30-MRSA-IVand ST93-
MRSA-IV were first isolated in 2001. In this study, PVL
was detected in 5 MRSA clones, including ST30-MRSA-
IV, ST93-MRSA-IV, ST8-MRSA-IV (pulsotype WA-
MRSA-12), ST59-MRSA-V, and ST583-MRSA-IV.
However, these 5 clones were infrequently isolated and
accounted for only 2.3% of all CA-MRSA. PVL genes
have been transmitted by a temperate phage designated
φPVL (36), which indicates that the PVL determinants are
transferable. Recently, a PVL-positive ST1-MRSA-IV
strain was isolated in Queensland (37) and New South
Wales (38), Australian states that have reported an increas-
ing incidence of ST30-MRSA-IV and ST93-MRSA-IV
(9–11). This finding suggests that the PVL determinants
are being transferred and raises the prospect that more CA-
MRSAin WAmay acquire PVLdeterminants in the future.
Some researchers have proposed that CA-MRSA may
arise either by hospital strains escaping into the communi-
ty, where they spread person to person, or de novo when
the SCCmec complex is acquired by a methicillin-suscep-
tible S. aureus isolate (24,39). In WA, the genetic back-
ground of nosocomial MRSA is different from that of
CA-MRSA, and therefore, community strains have likely
evolved independently of hospital strains. In addition, in
WA hospitals, apart from 2 single-strain outbreaks in a
large metropolitan hospital (ST1-MRSA-IV [13] and ST5-
MRSA-V (WA-MRSA-11 pulsotype), little evidence has
been found of CA-MRSA spreading within healthcare
facilities. Although person-to-person spread most likely
occurs in the community, the increasing number of MRSA
in the WA community may also be due to mobility of the
community SCCmec types. The genetic diversity of CA-
MRSA isolated in WA and the presence of at least 3
SCCmec types also support this possibility.
Conclusions
Although a comprehensive MRSA screening and con-
trol program has prevented the mEMRSA from emerging,
it has not prevented SCCmec type IV and type V MRSA
clones, including nmEMRSA (ST22-MRSA-IV) and CA-
MRSA, from becoming established in WA. SCCmec types
IV and V are now found in MRSA with distantly related
MRSA Clones, Western Australia
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type has been detected. Initially nonmultidrug-resistant,
many of these CA-MRSA clones have acquired plasmids
and chromosomal resistance determinants allowing some
strains to become resistant to up to 5 non–β-lactam antimi-
crobial agents, including erythromycin, tetracycline,
trimethoprim, ciprofloxacin, gentamicin, rifampin, fusidic
acid, and mupirocin. With the detection of 5 PVL-positive
clones and the recent emergence of PVL in a previously
reported PVL-negative CA-MRSA clone, more severe
staphylococcal disease caused by CA-MRSA can be
expected in the future. SCCmec types that can be acquired
by multiple genotypes of S. aureus over a short period and
the isolation of multidrug-resistant or PVL-positive CA-
MRSAare major public health concerns and emphasize the
importance of typing in tracing the origin of isolates and in
designing antimicrobial drug prescribing policies for their
control, if possible, in the community.
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